Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Ready Source of Functional Liver Cells Should Boost Drug Development Efforts

By LabMedica International staff writers
Posted on 09 Aug 2015
Liver function in newborns kicks in only after exposure to certain nutrient factors derived from gut bacteria, and this phenomenon has been used to differentiate pluripotent stem cells into fully functional liver cells (hepatocytes). More...


Investigators at the Hebrew University of Jerusalem (Israel) found that fetal hepatocytes acquired mature CYP450 (cytochrome P450) expression only after birth, suggesting that nutritional cues were required to drive hepatic maturation. Subsequently, they showed that vitamin K2 and lithocholic acid, a by-product of intestinal flora, activated pregnane X receptor (PXR) and CYP3A4 and CYP2C9 expression in isolated fetal hepatocytes.

Human pluripotent stem cells (hPSCs) represent an excellent source of differentiated hepatocytes; however, current protocols still produce fetal-like hepatocytes with limited mature function. In the current study, the investigators induced hPSCs to differentiate into fully functional mature hepatocytes by augmenting their growth medium with vitamin K2 and lithocholic acid.

They reported in the July 2015 issue of the journal Hepatology that differentiated cells produced albumin and apolipoprotein B100 at levels equivalent to primary human hepatocytes. Flow cytometry showed that over 83% of cells were albumin and hepatocyte nuclear factor 4 alpha (HNF4α) positive, which permitted high-content screening in a 96-well plate format. Stem cell–derived hepatocytes demonstrated all toxicological endpoints examined, including steatosis, apoptosis, and cholestasis, when exposed to nine known hepatotoxins.

“This is quite a revolution for pharmaceutical drug discovery,” said senior author Dr. Yaakov Nahmias, professor of bioengineering at the Hebrew University of Jerusalem. “While other groups have been able to produce liver cells before us, their cells showed little functional activity, and could not be reliably used for drug discovery. In fact, up until now stem cell-derived hepatocytes showed little ability to predict clinical outcome. The limited availability of functional hepatocytes for drug testing is a major bottleneck bringing pharmaceutical companies to spend USD one billion [per] year on liver cells alone. Our ability to produce an unlimited supply of functional liver cells from human pluripotent stem cells can change all that.”

Related Links:

Hebrew University of Jerusalem



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
DNA Extraction Kit
MagMAX DNA Multi-Sample Ultra 2.0 Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.